CRBP

TentativeAI Memo

Corbus

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Additional CANYON-1 data at ObesityWeek • 2026-11-17

Base target: $5 / p=45% prob

Biggest risk

CANYON-1 is an early, short-duration study, and the 60 mg cohort had higher adverse-event discontinuation than placebo. Larger trials may not reproduce the reported benefit; oncology response and registrational execution remain uncertain. [#8-K-2026-10-15] https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-ex99_1.htm

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The October company presentation confirms TEMPO-1 first-patient dosing and reports a 5% placebo-adjusted 12-week weight-loss result for CRB-913's 60 mg cohort. Additional obesity data and first-line oncology combination data provide distinct clinical opportunities. [#8-K-2026-10-15] https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-ex99_1.htm

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

First-line CRB-701 combination data
CRB-913 Phase 2 initiation
The October company presentation confirms TEMPO-1 first-patient dosing and reports a 5% placebo-adjusted 12-week weight-loss result for CRB-913's 60 mg cohort.

BearKey bullets

CANYON-1 adverse-event discontinuations were 12.9% in the 60 mg cohort versus 4.5% on placebo; longer and larger studies are needed to assess tolerability.
[#8-K-2026-10-15]
CRB-701 combination efficacy, TEMPO-1 enrollment, and future regulatory outcomes remain execution risks.

WatchKey bullets

Additional CANYON-1 data at ObesityWeek

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=45%)

Target spread vs base: +67% / -62%

Scenario probabilities

Bull Target: $8 (p=25%)Base Target: $5 (p=45%)Bear Target: $2 (p=30%)

Commentary

The $4.52 October 16 anchor is about 16% below the $5.38 October 9 anchor in the prior baseline; the cause is not established. The positive deterministic directional prior is tempered by that decline, low coverage, and unverified post-update analyst revisions. Zero-valued sentiment, options, short-interest, and employee fields denote unavailable measurements, not neutral readings.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

First-line CRB-701 combination data
CRB-913 Phase 2 initiation

Scenarios

Bull Target (Scenario probability)

$8 / p=25% prob

Base Target (Scenario probability)

$5 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-17
Additional CANYON-1 data at ObesityWeek
Corbus expects to present additional Phase 1b CRB-913 obesity data in November. Its October presentation reports 5% placebo-adjusted weight loss at 12 weeks for the 60 mg cohort, but adverse-event discontinuations were 12.9% versus 4.5% on placebo. Fuller efficacy and safety detail could materially change the interpretation. [#8-K-2026-10-15] https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-ex99_1.htm
Prob 85.00% • Move 18.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

First-line CRB-701 combination data
2027-03-31
Corbus expects topline response-rate data for CRB-701 plus pembrolizumab in first-line oropharyngeal cancer in Q1 2027. The result may inform further registration-enabling work; efficacy and safety remain unproven in that setting. [#8-K-2026-10-15] https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-ex99_1.htm
Prob 65% • Move 25% • Priced-in 25%
CRB-913 Phase 2 initiation
2027-06-30
Corbus expects to start a CRB-913 monotherapy Phase 2 study in the first half of 2027, subject to development planning and execution. Initiation would advance the program but would not establish efficacy. [#8-K-2026-10-15] https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-ex99_1.htm
Prob 70% • Move 10% • Priced-in 20%

Risks

CANYON-1 adverse-event discontinuations were 12.9% in the 60 mg cohort versus 4.5% on placebo; longer and larger studies are needed to assess tolerability. [#8-K-2026-10-15]
CRB-701 combination efficacy, TEMPO-1 enrollment, and future regulatory outcomes remain execution risks. [#8-K-2026-10-15]
Clinical comparisons shown against other obesity treatments are cross-trial observations, not head-to-head evidence. [#8-K-2026-10-15]
Q2 2026 R&D expense rose to $31.2 million from $15.2 million a year earlier, creating financing and dilution risk as trials advance. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
IPHA	Nectin-4 ADC development reference from the prior baseline, but payload, tumor mix, and stage differ from CRB-701; not a like-for-like valuation multiple.
SKYE	CB1-mechanism development reference from the prior baseline, but its injectable antibody differs from Corbus's oral inverse agonist; not a direct valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

IPHA

Nectin-4 ADC development reference from the prior baseline, but payload, tumor mix, and stage differ from CRB-701; not a like-for-like valuation multiple.

SKYE

CB1-mechanism development reference from the prior baseline, but its injectable antibody differs from Corbus's oral inverse agonist; not a direct valuation multiple.